Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7601925 | 0.81 | MAOA (0.42) | MAOAMAOB | |
| SCHEMBL8423019 | 0.77 | PTGS2 (0.63) | PTGS2PTGS1LOX | |
| SCHEMBL17205245 | 0.70 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL4940447 | 0.70 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL28111372 | 0.69 | PTGS2 (0.58) | PTGS2PTGS1 | |
| SCHEMBL8487954 | 0.67 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL4941143 | 0.67 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL5709000 | 0.67 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL7108267 | 0.67 | PTGS2 (0.46) | PTGS2PTGS1LOX | |
| SCHEMBL6050679 | 0.67 | PTGS2 (0.76) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299372-A1 | PYRONES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC. (CA) | 2003-04-09 | — | — | EP | disclosed |
| US-6465509-B2 | FOR THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISEASE SUSCEPTIBLE TO TREATMENT WITH A NON-STEROIDAL ANTI-INFLAMMATORY AGENT | MERCK FROSST CANADA & CO. (CA) | 2002-10-15 | — | — | US | disclosed |
| US-20020058690-A1 | For therapy and prophylaxis of inflammatory disease susceptible to treatment with a non- steroidal anti-inflammatory agent | MERCK FROSST CANADA LTD. (CA) | 2002-05-16 | — | — | US | disclosed |
| WO-2002002547-A1 | PYRONES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA & CO. (CA) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058690-A1 | For therapy and prophylaxis of inflammatory disease susceptible to treatment with a non- steroidal anti-inflammatory agent | PTGS1, PTGES2, PTGS2 | PTGS2 3/4885PTGS1 1/4885MAOA 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.